Fiona Wightman

2.3k total citations
24 papers, 1.3k citations indexed

About

Fiona Wightman is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Fiona Wightman has authored 24 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Infectious Diseases, 15 papers in Virology and 11 papers in Epidemiology. Recurrent topics in Fiona Wightman's work include HIV Research and Treatment (15 papers), HIV/AIDS drug development and treatment (10 papers) and Hepatitis B Virus Studies (8 papers). Fiona Wightman is often cited by papers focused on HIV Research and Treatment (15 papers), HIV/AIDS drug development and treatment (10 papers) and Hepatitis B Virus Studies (8 papers). Fiona Wightman collaborates with scholars based in Australia, United States and Denmark. Fiona Wightman's co-authors include Sharon R. Lewin, Paul Cameron, Ajantha Solomon, Suha Saleh, Melissa J. Churchill, Paula Ellenberg, Thomas A. Rasmussen, Lars Østergaard, Jenny L. Anderson and Ole S. Søgaard and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Blood and PLoS ONE.

In The Last Decade

Fiona Wightman

24 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fiona Wightman Australia 17 944 568 490 326 247 24 1.3k
Sifei Xing United States 9 822 0.9× 585 1.0× 344 0.7× 256 0.8× 273 1.1× 9 1.1k
M Groenink Netherlands 13 1.2k 1.3× 833 1.5× 466 1.0× 200 0.6× 251 1.0× 17 1.4k
Marie-Anne Rey-Cuillé France 12 650 0.7× 330 0.6× 427 0.9× 306 0.9× 160 0.6× 16 957
Yoshiyuki Yokomaku Japan 20 699 0.7× 654 1.2× 193 0.4× 283 0.9× 366 1.5× 60 1.1k
Richard D. Sloan Canada 21 785 0.8× 650 1.1× 292 0.6× 278 0.9× 377 1.5× 37 1.2k
Sandrina DaFonseca Canada 16 937 1.0× 495 0.9× 687 1.4× 253 0.8× 183 0.7× 19 1.3k
Gian Paolo Rizzardi Italy 19 861 0.9× 592 1.0× 580 1.2× 327 1.0× 208 0.8× 36 1.4k
Natalia Soriano-Sarabia United States 17 760 0.8× 408 0.7× 555 1.1× 268 0.8× 144 0.6× 42 1.1k
Adam A. Capoferri United States 14 1.5k 1.6× 970 1.7× 603 1.2× 334 1.0× 225 0.9× 24 1.7k
Ellen G. Harrer Germany 16 932 1.0× 401 0.7× 699 1.4× 279 0.9× 249 1.0× 34 1.3k

Countries citing papers authored by Fiona Wightman

Since Specialization
Citations

This map shows the geographic impact of Fiona Wightman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fiona Wightman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fiona Wightman more than expected).

Fields of papers citing papers by Fiona Wightman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fiona Wightman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fiona Wightman. The network helps show where Fiona Wightman may publish in the future.

Co-authorship network of co-authors of Fiona Wightman

This figure shows the co-authorship network connecting the top 25 collaborators of Fiona Wightman. A scholar is included among the top collaborators of Fiona Wightman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fiona Wightman. Fiona Wightman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mota, Talia M., Thomas A. Rasmussen, Ajantha Rhodes, et al.. (2017). No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapy. AIDS. 31(8). 1137–1141. 8 indexed citations
2.
Rasmussen, Thomas A., Jenny L. Anderson, Fiona Wightman, & Sharon R. Lewin. (2016). Cancer therapies in HIV cure research. Current Opinion in HIV and AIDS. 12(1). 96–104. 17 indexed citations
3.
Anderson, Jenny L., Talia M. Mota, Vanessa A. Evans, et al.. (2016). Understanding Factors That Modulate the Establishment of HIV Latency in Resting CD4+ T-Cells In Vitro. PLoS ONE. 11(7). e0158778–e0158778. 8 indexed citations
4.
Lu, Hao, Lachlan Gray, Fiona Wightman, et al.. (2014). Ex Vivo Response to Histone Deacetylase (HDAC) Inhibitors of the HIV Long Terminal Repeat (LTR) Derived from HIV-Infected Patients on Antiretroviral Therapy. PLoS ONE. 9(11). e113341–e113341. 21 indexed citations
5.
Badley, Andrew D., et al.. (2013). Altering cell death pathways as an approach to cure HIV infection. Cell Death and Disease. 4(7). e718–e718. 60 indexed citations
6.
Rasmussen, Thomas A., Ole S. Søgaard, Christel R. Brinkmann, et al.. (2013). Comparison of HDAC inhibitors in clinical development. Human Vaccines & Immunotherapeutics. 9(5). 993–1001. 149 indexed citations
7.
Wightman, Fiona, Hao Lu, Ajantha Solomon, et al.. (2013). Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells. AIDS. 27(18). 2853–2862. 60 indexed citations
8.
Smith, Miranda Z., Fiona Wightman, & Sharon R. Lewin. (2012). HIV Reservoirs and Strategies for Eradication. Current HIV/AIDS Reports. 9(1). 5–15. 45 indexed citations
9.
Saleh, Suha, Fiona Wightman, Marina R. Alexander, et al.. (2011). Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cells. Retrovirology. 8(1). 80–80. 72 indexed citations
10.
Wightman, Fiona, Ajantha Solomon, Gabriela Khoury, et al.. (2010). Both CD31+and CD31−Naive CD4+T Cells Are Persistent HIV Type 1–Infected Reservoirs in Individuals Receiving Antiretroviral Therapy. The Journal of Infectious Diseases. 202(11). 1738–1748. 94 indexed citations
11.
Crane, Megan, Sunee Sirivichayakul, Judy Chang, et al.. (2010). No Increase in Hepatitis B Virus (HBV)-Specific CD8+T Cells in Patients with HIV-1-HBV Coinfections following HBV-Active Highly Active Antiretroviral Therapy. Journal of Virology. 84(6). 2657–2665. 16 indexed citations
12.
Shehu-Xhilaga, Miranda, David Rhodes, Fiona Wightman, et al.. (2009). The novel histone deacetylase inhibitors metacept-1 and metacept-3 potently increase HIV-1 transcription in latently infected cells. AIDS. 23(15). 2047–2050. 32 indexed citations
13.
Chang, Judy, Alexander Thompson, Kumar Visvanathan, et al.. (2007). The phenotype of hepatitis B virus–specific T cells differ in the liver and blood in chronic hepatitis B virus infection. Hepatology. 46(5). 1332–1340. 41 indexed citations
14.
15.
Solomon, Ajantha, Natalie Lane, Fiona Wightman, Paul R. Gorry, & Sharon R. Lewin. (2005). Enhanced Replicative Capacity and Pathogenicity of HIV-1 Isolated From Individuals Infected With Drug-Resistant Virus and Declining CD4+ T-Cell Counts. JAIDS Journal of Acquired Immune Deficiency Syndromes. 40(2). 140–148. 14 indexed citations
16.
Lewin, Sharon R., et al.. (2005). A randomised controlled trial of oral zinc on the immune response to tuberculosis in HIV-infected patients.. PubMed. 9(12). 1378–84. 26 indexed citations
17.
18.
Wightman, Fiona, et al.. (2004). Highly reproducible transient transfections for the study of hepatitis B virus replication based on an internal GFP reporter system. Journal of Virological Methods. 121(1). 65–72. 2 indexed citations
19.
Wightman, Fiona, Tomos E. Walters, Anna Ayres, et al.. (2004). Comparison of Sequence Analysis and a Novel Discriminatory Real-Time PCR Assay for Detection and Quantification of Lamivudine-Resistant Hepatitis B Virus Strains. Journal of Clinical Microbiology. 42(8). 3809–3812. 22 indexed citations
20.
Colledge, Danni, Timothy J. Shaw, S. Bowden, et al.. (2002). The purine nucleotide analogue LY582563 (mcc-478) inhibits replication of wild type and drug resistant hepatitis b virus. Journal of Hepatology. 36. 88–88. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sifei Xing Breakdown of academic impact, for papers by M Groenink Breakdown of academic impact, for papers by Marie-Anne Rey-Cuillé Breakdown of academic impact, for papers by Yoshiyuki Yokomaku Breakdown of academic impact, for papers by Richard D. Sloan Breakdown of academic impact, for papers by Sandrina DaFonseca Breakdown of academic impact, for papers by Gian Paolo Rizzardi Breakdown of academic impact, for papers by Natalia Soriano-Sarabia Breakdown of academic impact, for papers by Adam A. Capoferri Breakdown of academic impact, for papers by Ellen G. Harrer
Rankless by CCL
2026